Skip to main content
Clinical Trials/NCT03845569
NCT03845569
Completed
Not Applicable

Impact of Habitual Protein Intake on Estimates of Dietary Protein Requirements in Resistance Trained Athletes

University of Toronto1 site in 1 country5 target enrollmentNovember 1, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Protein/Amino Acid Metabolism
Sponsor
University of Toronto
Enrollment
5
Locations
1
Primary Endpoint
Phenylalanine excretion (F13CO2)
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

Protein is an essential nutrient that one's diet to maintain important bodily functions and to recover from exercise. Currently, the Indicator Amino Acid Oxidation method (IAAO) has been used to determine protein requirements in a variety of populations including children, neonates, the elderly and recently, resistance trained populations. This study serves to test the robustness of the IAAO method and to determine if high habitual dietary protein intake, as seen in resistance trained males, has the potential to influence the protein requirements determined by the IAAO method. Further, the current study also aims to determine how the body metabolizes or uses dietary protein and how it might change when consuming a protein intake that is less than what is habitually consumed.

Detailed Description

This study employed a two-phase randomized crossover design, where participants performed both a High/Habitual protein phase and a moderate protein phase. The Habitual protein phase is designed to model resistance trained individual's habitual protein consumption by providing 2.2g/kg/d in a controlled diet. The Moderate protein phase is designed to investigate the impact of decreasing dietary protein intake to a moderate amount (1.2g/kg/d) over five days on protein metabolism. Both phases used the stable isotope L-\[1-13C\]Phenylalanine and metabolic trails were modelled after the indicator amino acid oxidation (IAAO) technique. High Protein Phase The high protein phase is three days in length, with diet-controlled throughout, and a metabolic trail on day 3. Participants will perform whole-body resistance exercise on days one and three. Moderate protein phase The Moderate protein phase is seven days in length, with MT on days three, five and seven. Dietary intake will be controlled throughout the whole phase providing either 2.2 g/kg/d of protein (days one and two), or 1.2 g/kg/d (days three through seven). Full body resistance exercise will be performed performed on days one, three, five and seven. This phase will allow measurement of protein metabolism over five days following a decrease in dietary protein intake, and to determine the effect of dietary changes on the IAAO method.

Registry
clinicaltrials.gov
Start Date
November 1, 2017
End Date
April 18, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Crossover
Sex
Male

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Daniel Moore

Principle Investigator

University of Toronto

Eligibility Criteria

Inclusion Criteria

  • Healthy, weight-trained individuals that have trained consistently for \> 1 year
  • Habitually dietary protein consumption of 1.9 to 3.0g/kg/d
  • Train each muscle group (i.e. chest, back, legs) at least twice a week
  • Body mass stable in the last month
  • Meets strength relative-to-weight guidelines (adapted from Morton et al., 2016; Chilibeck et -al., 1997)
  • Bench Press: - Bodyweight (kg) \* 1.25
  • Leg Press: - Bodyweight (kg) \*4.0

Exclusion Criteria

  • Inability to meet health and PA guidelines according to the PAR-Q+
  • Inability to adhere to any of the protocol guidelines (e.g. alcohol and caffeine consumption)
  • Regular tobacco use, screened by questionnaire
  • Illicit drug use (e.g. growth hormone, testosterone, etc.), screened by a survey in training log
  • 1 month sedentary in the last 6 months prior to study participation
  • 30 minutes of continuous cardio per exercise session
  • BMI \> or equal to 35
  • Individual plans to increase or decrease body mass in the next 3 months
  • Use of supplements (excluding whey protein), such as creatine and beta-alanine, in the last 30 days

Outcomes

Primary Outcomes

Phenylalanine excretion (F13CO2)

Time Frame: Through study completion, an average of 3 months

Expressed as µmol/kg/h; phenylalanine excretion is determined via breath enrichment (F13CO2) of the oral tracer. Breath 13CO2 enrichment was measured by continuous-flow isotope ratio mass spectrometry

Phenylalanine oxidation (PheOX)

Time Frame: Through study completion, an average of 3 months

Expressed as µmol/kg/h; phenylalanine excretion is determined via breath and urine enrichment of the oral tracer. Breath 13CO2 enrichment was measured by continuous-flow isotope ratio mass spectrometry and urinary L-\[1-13C\] phenylalanine was measured by liquid chromatography tandem mass spectrometry

Secondary Outcomes

  • Phenylalanine Rate of Appearance (PheRa/Flux)(Through study completion, an average of 3 months)
  • Net Protein Balance(Through study completion, an average of 3 months)

Study Sites (1)

Loading locations...

Similar Trials